Free Trial
NASDAQ:GYRE

Gyre Therapeutics Q1 2025 Earnings Report

Gyre Therapeutics logo
$7.19 -0.01 (-0.14%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$7.19 +0.00 (+0.01%)
As of 08/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gyre Therapeutics EPS Results

Actual EPS
$0.03
Consensus EPS
$0.03
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Gyre Therapeutics Revenue Results

Actual Revenue
$22.06 million
Expected Revenue
$28.40 million
Beat/Miss
Missed by -$6.34 million
YoY Revenue Growth
N/A

Gyre Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
6:00AM ET

Upcoming Earnings

Gyre Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025

Gyre Therapeutics Earnings Headlines

Gyre Therapeutics (GYRE) Projected to Post Quarterly Earnings on Tuesday
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE), a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

View Gyre Therapeutics Profile

More Earnings Resources from MarketBeat